Our work is for instance in accordance with studies showing that the pharmacologic inhibition of LXR by the inverse agonist SR9243, enhances dendritic cell activity that is suppressed by tumor-produced LXR ligands, and induces in vivo control of triple-negative breast cancers (TNBC) through the stimulation of CD8+ T-cell cytotoxic activity [54, 55]. This evidence concerns the gene CD8A and neoplasm.